Drug-eluting bead transarterial chemoembolization as neoadjuvant therapy pre-liver transplantation for advanced-stage hepatocellular carcinoma

Table 2 Baseline subgroup disease characteristics

Characteristic	Without segmental PVTT		P value	With segmental PVTT		P value
	Group A, n = 31, 68.9%	Group C, n = 37, 68.5%		Group B, n = 14, 31.1%	Group D, n = 17, 31.5%
AFP level at admission in ng/mL	155.9 (11.9, 1386.6)	22.6 (7.2, 297.9)	0.121	5428.8 (33.5, 20000)	172.2 (54.5, 7951.4)	0.233
AFP level before LT in ng/mL	26.5 (4.6, 200.6)	22.6 (7.2, 297.9)	0.703	459.9 (4.6, 7670.5)	172.2 (54.5, 7951.4)	0.953
Overall diameter of target tumors in cm	6.3 (4.4, 9.6)	8.0 (4.9, 11.0)	0.449	9.4 (6.6, 16.6)	8.0 (6.1, 11.5)	0.361
Tumor grade, n (%)			0.925			> 0.99
Well differentiated	1 (3.2)	1 (2.7)		0 (0.0)	1 (5.9)
Moderately differentiated	22 (71.0)	27 (73.0)		11 (78.6)	11 (64.7)
Undifferentiated	8 (25.8)	9 (24.3)		3 (21.4)	5 (29.4)
MVI, n (%)			< 0.01			-
MVI = M0	13 (41.9)	11 (29.7)		-	-
MVI = M1	10 (32.3)	6 (16.2)		-	-
MVI = M2	8 (25.8)	20 (54.1)		-	-

AFP: Alpha-fetoprotein; LT: Liver transplantation; MVI: Microvascular invasion; PVTT: Portal vein tumor thrombus.